LAB Q2 2020 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$370M

Q2 2020 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$26M-7.6% YoY

Gross Profit

$15M58.9% margin

Operating Income

-$14M-52.7% margin

Net Income

-$13M-49.9% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

-5.6%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$282M

Total Liabilities

$150M

Stockholders' Equity

$133M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$28M	-7.6%
Gross Profit	$15M	$15M	-0.2%
Operating Income	-$14M	-$15M	+6.2%
Net Income	-$13M	-$14M	+5.4%

Revenue Segments

Product

$17M40%

Consumables

$9M20%

Instruments

$9M20%

Service

$5M12%

Collaboration Revenue

$3M7%

Product and Service, Other

$513,0001%

Grant

$450,0001%

License

$63,0000%

Geographic Segments

Americas

$14M53%

EMEA

$7M25%

Asia Pacific

$6M21%